Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Genentech buys liver disease–focused Jecure

by Lisa M. Jarvis
December 1, 2018 | A version of this story appeared in Volume 96, Issue 48

 

Genentech has agreed to buy Jecure Therapeutics for an undisclosed sum. San Diego–based Jecure came out of stealth last year with $20 million from Versant Ventures to develop small molecules for nonalcoholic steatohepatitis (NASH), a serious liver disease. The deal gives Genentech a portfolio of early-stage compounds that block NLRP3, an immunomodulatory protein that helps trigger cellular inflammatory responses. In addition to NASH, NLRP3 inhibitors could be relevant in gout, inflammatory bowel disease, and cardiovascular diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.